M Kůta

448 total citations
5 papers, 382 citations indexed

About

M Kůta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M Kůta has authored 5 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 1 paper in Molecular Biology. Recurrent topics in M Kůta's work include Lung Cancer Treatments and Mutations (3 papers), Cancer Treatment and Pharmacology (2 papers) and Lung Cancer Research Studies (2 papers). M Kůta is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Cancer Treatment and Pharmacology (2 papers) and Lung Cancer Research Studies (2 papers). M Kůta collaborates with scholars based in Czechia, Spain and France. M Kůta's co-authors include Jaromı́r Roubec, Petr Zatloukal, Giuseppe Giaccone, Setareh Shamsili, Karijn Floor, Adrie Gunther, Rob J. van Klaveren, Luboš Petruželka, Vı́tězslav Kolek and Jana Skřičková and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Molecular Cancer Therapeutics.

In The Last Decade

M Kůta

4 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M Kůta Czechia	3	224	205	152	47	39	5	382
Helen Pak Canada	7	126 0.6×	357 1.7×	111 0.7×	64 1.4×	35 0.9×	7	499
Bastianina Canu Italy	10	197 0.9×	136 0.7×	103 0.7×	84 1.8×	22 0.6×	15	346
Archana Sehrawat United States	8	173 0.8×	195 1.0×	136 0.9×	67 1.4×	28 0.7×	10	398
F. R. Hirsch United States	9	247 1.1×	220 1.1×	222 1.5×	71 1.5×	15 0.4×	26	449
Hengyu Lu United States	8	111 0.5×	158 0.8×	55 0.4×	51 1.1×	25 0.6×	11	269
Mary E. Rothstein United States	8	284 1.3×	251 1.2×	204 1.3×	77 1.6×	110 2.8×	10	537
Laia Perez‐Roca Spain	9	137 0.6×	212 1.0×	197 1.3×	124 2.6×	26 0.7×	11	393
Jenna Wheelhouse United States	8	215 1.0×	211 1.0×	69 0.5×	94 2.0×	16 0.4×	9	375
Ben Staal United States	9	140 0.6×	219 1.1×	62 0.4×	61 1.3×	27 0.7×	14	365
Susan D’Aloisio Canada	4	140 0.6×	262 1.3×	130 0.9×	89 1.9×	38 1.0×	7	408

Countries citing papers authored by M Kůta

Since Specialization

Citations

This map shows the geographic impact of M Kůta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Kůta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Kůta more than expected).

Fields of papers citing papers by M Kůta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Kůta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Kůta. The network helps show where M Kůta may publish in the future.

Co-authorship network of co-authors of M Kůta

This figure shows the co-authorship network connecting the top 25 collaborators of M Kůta. A scholar is included among the top collaborators of M Kůta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Kůta. M Kůta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Giaccone, Giuseppe, Petr Zatloukal, Jaromı́r Roubec, et al.. (2009). Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(27). 4481–4486. 210 indexed citations

2.

Giaccone, Giuseppe, Petr Zatloukal, Jaromı́r Roubec, et al.. (2007). A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 6. 2 indexed citations

3.

Baselga, José, Antonio Llombart‐Cussac, Meritxell Bellet, et al.. (2003). Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Annals of Oncology. 14(9). 1383–1390. 30 indexed citations

4.

Zatloukal, Petr, Luboš Petruželka, Milada Zemanová, et al.. (2003). Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 41(3). 321–331. 139 indexed citations

5.

Petruželka, Luboš, J. Fischer, M Kůta, et al.. (1998). [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].. PubMed. 99(1). 25–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact